Cedarburg Hauser Pharmaceuticals is an experienced, contract development and manufacturing company for active pharmaceutical ingredients (API) and pharmaceutical intermediates that combines the benefits of working with a contract research organization (CRO) and a contract manufacturing organization.
Cedarburg Pharmaceuticals, Inc. to Be Acquired by Albany Molecular Research, Inc.
GRAFTON, Wis., March 24, 2014 /PRNewswire/ — Cedarburg Pharmaceuticals, Inc. today announced that it has signed a definitive agreement to be acquired by Albany Molecular Research Inc., a global contract research and manufacturing organization. The transaction is expected to close in early April 2014. Theron E. Odlaug, Ph.D., Cedarburg's executive chairman, commented, "The Company's board […]
Cedarburg Hauser Hires Alex Tretyakov as Director of Process Development
GRAFTON, Wis., Feb. 11, 2014 /PRNewswire/ — Cedarburg Hauser Pharmaceuticals (CHP), an experienced contract development and manufacturing organization (CDMO) specializing in small molecule APIs, has announced the hire Alex Tretyakov, Ph.D. as its Director of Process Development. "In his 25 plus years of industry experience Alex has demonstrated a real ability to streamline processes and drive growth via […]
Cedarburg Hauser Upgrades API Manufacturing Plant
GRAFTON, Wis., Sept. 18, 2013 /PRNewswire/ — Cedarburg Hauser Pharmaceuticals (CHP) announces the improvement of its Active Pharmaceutical Ingredient (API) plant in Grafton, WI. These upgrades are a continuation of a long-term capital improvement initiative that results from an increased demand for the contract manufacturing of commercial APIs. "Our customer's demand for Cedarburg Hauser commercial APIs continues […]
Cedarburg Hauser Pharmaceuticals Receives CMO Leadership Award in Productivity
GRAFTON, Wis., Aug. 8, 2013 /PRNewswire/ — Cedarburg Hauser Pharmaceuticals (CHP), a contract development and manufacturing organization (CDMO), announces the receipt of a CMO Leadership Award for excellence in productivity. This is the second consecutive year CHP has received an award in this category. (Logo: http://photos.prnewswire.com/prnh/20130808/PH60817LOGO) "Receiving a CMO Leadership Award in productivity for a second […]
Cedarburg Hauser Granted DEA Registration for Denver Manufacturing Facility
DENVER, Feb. 27, 2013 /PRNewswire/ — Cedarburg Hauser Pharmaceuticals (CHP), a contract development and manufacturing organization (CDMO), announced today that its Denver, Colorado facility has been granted registration as a manufacturer of schedule II-V controlled substances by the U.S Drug Enforcement Agency (DEA). The new DEA registration status is the result of a concerted effort to […]
Cedarburg Hauser Promotes John K. Lynch to Chief Scientific Officer
GRAFTON, Wis., Nov. 6, 2012 /PRNewswire/ — Cedarburg Hauser Pharmaceuticals (CHP), an experienced contract development and manufacturing organization (CDMO), has announced the appointment of John K. Lynch, Ph.D. as its Chief Scientific Officer (CSO). Dr. Lynch has served as Cedarburg Hauser's Director of Research and Development for the last three years, where he oversaw development projects […]
Cedarburg Hauser Adds Plant Capacity
Makes Additional Capital Investments in Response to Demand for Commercial API GRAFTON, Wis., Sept. 25, 2012 /PRNewswire/ — Cedarburg Hauser Pharmaceuticals (CHP) has expanded the capacity of its Wisconsin-based active pharmaceutical ingredient (API) manufacturing plant. The expansion efforts are a result of an increased demand for contract manufacturing of commercial APIs and are accompanied by […]
